Nonclinical safety evaluation of sunitinib: a potent inhibitor of VEGF, PDGF, KIT, FLT3, and RET receptors.

Abstract

Sunitinib malate (SUTENT) is a multitargeted receptor tyrosine kinase (RTK) inhibitor that is approved multinationally for the treatment of imatinib-resistant/-intolerant gastrointestinal stromal tumor and advanced renal cell carcinoma. This paper characterizes the organ toxicity of sunitinib in Sprague-Dawley rats and cynomolgus monkeys, and the… (More)
DOI: 10.1177/0192623308326151

Topics

Cite this paper

@article{Patyna2008NonclinicalSE, title={Nonclinical safety evaluation of sunitinib: a potent inhibitor of VEGF, PDGF, KIT, FLT3, and RET receptors.}, author={Shem Patyna and Claudio Arrigoni and Andrea Terron and Tae-Won Kim and Joyce K Heward and Steven L. Vonderfecht and Robert H. Denlinger and Susan E. Turnquist and Winston E N Evering}, journal={Toxicologic pathology}, year={2008}, volume={36 7}, pages={905-16} }